The AML Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

FLT3 inhibitors

FLT3 inhibitors

FLT3 is expressed mainly in hematopoietic progenitors and dendritic cells, and its constitutive activation induces signaling cascades, which suppress normal regulation of apoptosis, differentiation, and proliferation in leukemic cells. FLT3 inhibitors are tyrosine kinase inhibitors that compete for the ATP binding site in the active domain of the kinase, inhibiting the ability of the protein to be phosphorylated, leading to a reduction in levels of that protein.

| |

All Interventions